{
    "clinical_study": {
        "@rank": "36806", 
        "arm_group": [
            {
                "arm_group_label": "Monosialoganglioside(GM1)", 
                "arm_group_type": "Active Comparator", 
                "description": "Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3"
            }, 
            {
                "arm_group_label": "normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo 80mg + N.S 250ml,qd,D0-D3"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the efficacy and safety of Monosialoganglioside(GM1) to prevent the neurotoxicity\n      induced by cisplatin"
        }, 
        "brief_title": "Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "NSCLC patients received a cisplatin-based doublet chemotherapy are included in this trial.\n      Patients are randomly assigned into the experimental group and control group based on\n      segmented block randomized method. After enrollment, patients should complete four or six\n      chemotherapy and GM1/placebo injection. During the 3w per cycle chemotherapy, cisplatin\n      injection is conducted in D1/D1-3, GM1/placebo (80mg+250ml N.S) is injected from D0 to D3.\n      Neurotoxicity evaluation and quality of life (FACT-NTX and EROTC scale) assessment will be\n      conducted every cycle and 3w/11w/19w after the chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cytological and histological confirmation of non-small cell lung cancer (NSCLC)\n             diagnosis, single sputum cytology diagnosis is not accepted\n\n          -  Expected survival period is more than 3 months\n\n          -  Enough blood function reservation: absolute neutrophil count (ANC) 2 x 10E9/L or\n             higher;platelet count 100 x 109 /L or higher;hemoglobin 9 g/dL or higher.\n\n          -  Enough liver function reservation:the total bilirubin less than upper limit of\n             normal;AST and ALT acuities were less than 2.5 times the upper limit of normal\n             (ULN);Alkaline phosphatase 5 times the upper limit of normal (ULN) or less.\n\n          -  Clinical doctors identify patients suitable for standard doses of ganglioside drug\n             therapy, and expected time of medication is at least six weeks\n\n          -  Within 4 weeks before treatment, did not receive other adverse reaction of drugs may\n             cause similar neurotoxicity; 18 weeks before, did not received platinum-based drugs\n             chemical treatment.\n\n          -  No more than 1 degree of the peripheral nervous system diseases exists before\n             enrollment, also no other  symptom or disease could affect the adverse reactions of\n             neurotoxicity pathological.\n\n          -  Can't accept other adverse reactions may prevent neurotoxicity treatment or care\n             after enrollment.\n\n          -  Sign the informed consent form.\n\n        Exclusion Criteria:\n\n          -  Patients with poor general condition, PS score more than 2 points\n\n          -  Women in pregnancy or lactation\n\n          -  Patients (male or female) have fertility possibility but not willing to or not to\n             adopt effective contraception\n\n          -  With other neurological dysfunction which can cause inaccurate record of the\n             occurrence of neurotoxicity and severity\n\n          -  Known or assignment of any of these products to test drugs allergic agent composition\n\n          -  Doctors think inappropriate for patients with ganglioside medication or estimated\n             time of less than 6 weeks\n\n          -  Active infection (determined by the researcher)\n\n          -  According to the researcher's judgment, there is serious disease to endanger the\n             safety of patients, or may prevent the patients from completing the study\n\n          -  Have a clear history of neurological or psychiatric disorders, including epilepsy or\n             dementia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882621", 
            "org_study_id": "GM1-0324"
        }, 
        "intervention": [
            {
                "arm_group_label": "Monosialoganglioside(GM1)", 
                "description": "80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.", 
                "intervention_name": "Monosialoganglioside(GM1)", 
                "intervention_type": "Drug", 
                "other_name": "Monosialotetrahexosylganglioside Sodium Injection"
            }, 
            {
                "arm_group_label": "normal saline", 
                "description": "80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.", 
                "intervention_name": "normal saline", 
                "intervention_type": "Drug", 
                "other_name": "normal saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NSCLC", 
            "Monosialoganglioside(GM1)", 
            "neurotoxicity"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "zhouting@sysucc.org.cn", 
                "last_name": "Ting Zhou", 
                "phone": "8602087343786"
            }, 
            "facility": {
                "address": {
                    "city": "GuangZhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510030"
                }, 
                "name": "Sun Yat-Sen University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Yan Huang, Doctor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients.", 
        "other_outcome": {
            "measure": "the quality of life of patients", 
            "safety_issue": "Yes", 
            "time_frame": "up to 19 weeks after the cisplatin based chemotherapy"
        }, 
        "overall_contact": {
            "email": "zhouting@sysucc.org.cn", 
            "last_name": "Ting Zhou", 
            "phone": "86-020-87343786"
        }, 
        "overall_contact_backup": {
            "email": "mayx@sysucc.org.cn", 
            "last_name": "YuXiang Ma", 
            "phone": "86-020-87343786"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "LI Zhang, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "incidence rate of neurotoxicity adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "up to 19 weeks after cisplatin chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882621"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Li Zhang", 
            "investigator_title": "Profressor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "neurotoxicity adverse events alleviation time", 
            "safety_issue": "Yes", 
            "time_frame": "up to 19 weeks after the cisplatin based chemotherapy"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": {
                "agency": "Southern Medical University, China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}